Use of an anti-D-alloimmunization kinetics model to correct the interval censored D-alloimmunization rate following red blood cell transfusions.

IF 2.5 3区 医学 Q2 HEMATOLOGY
Transfusion Pub Date : 2025-05-01 Epub Date: 2025-02-05 DOI:10.1111/trf.18138
Emil Ainsworth Jochumsen, Kathleen Selleng, Jay S Raval, Carolina Bonet Bub, Jose M Kutner, Ulrik Sprogøe, Mark H Yazer
{"title":"Use of an anti-D-alloimmunization kinetics model to correct the interval censored D-alloimmunization rate following red blood cell transfusions.","authors":"Emil Ainsworth Jochumsen, Kathleen Selleng, Jay S Raval, Carolina Bonet Bub, Jose M Kutner, Ulrik Sprogøe, Mark H Yazer","doi":"10.1111/trf.18138","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The rate of D-alloimmunization amongst RhD-negative recipients of RhD-positive red blood cell (RBC) transfusions is not certain. Recipients with a short duration between the index RhD-positive transfusion and the last antibody detection test that did not show anti-D might become D-alloimmunized in the future. A regression model was developed to predict how often such patients might develop D-alloimmunization in the future to help account for the immunohematological uncertainty that accompanies having short serological follow up periods.</p><p><strong>Methods: </strong>Using the published literature on recipients who were intentionally transfused with RhD-positive RBCs and serially followed with antibody screens, as well as unpublished datasets, a regression model was constructed to demonstrate the timing of D-alloimmunization for recipients who became D-alloimmunized within 6 months following the index transfusion. The model was then applied to a series of RhD-negative hospitalized recipients of at least one unit of RhD-positive RBCs who did not become D-alloimmunized but who had fewer than 6 months of serological follow up to weight their contribution to the D-alloimmunization rate.</p><p><strong>Results: </strong>Overall, the rate of D-alloimmunization was 21/105 (20.0%). There were 39 patients whose last documented antibody screen was performed between 14 days and 6 months after the index RhD-positive transfusion, and these patients were entered into the weighted model. After applying the model, the D-alloimmunization rate rose to 26.3%.</p><p><strong>Conclusion: </strong>Using a weighted model can help reduce the immunohematological uncertainty that accompanies the inclusion of patients with relatively short serological follow up in studies of RBC alloimmunization.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":"S304-S312"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035998/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/trf.18138","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The rate of D-alloimmunization amongst RhD-negative recipients of RhD-positive red blood cell (RBC) transfusions is not certain. Recipients with a short duration between the index RhD-positive transfusion and the last antibody detection test that did not show anti-D might become D-alloimmunized in the future. A regression model was developed to predict how often such patients might develop D-alloimmunization in the future to help account for the immunohematological uncertainty that accompanies having short serological follow up periods.

Methods: Using the published literature on recipients who were intentionally transfused with RhD-positive RBCs and serially followed with antibody screens, as well as unpublished datasets, a regression model was constructed to demonstrate the timing of D-alloimmunization for recipients who became D-alloimmunized within 6 months following the index transfusion. The model was then applied to a series of RhD-negative hospitalized recipients of at least one unit of RhD-positive RBCs who did not become D-alloimmunized but who had fewer than 6 months of serological follow up to weight their contribution to the D-alloimmunization rate.

Results: Overall, the rate of D-alloimmunization was 21/105 (20.0%). There were 39 patients whose last documented antibody screen was performed between 14 days and 6 months after the index RhD-positive transfusion, and these patients were entered into the weighted model. After applying the model, the D-alloimmunization rate rose to 26.3%.

Conclusion: Using a weighted model can help reduce the immunohematological uncertainty that accompanies the inclusion of patients with relatively short serological follow up in studies of RBC alloimmunization.

使用抗d -异体免疫动力学模型来纠正红细胞输注后间隔缺失的d -异体免疫率。
在接受rhd阳性红细胞(RBC)输注的rhd阴性受体中,d异体免疫率尚不确定。在指数rh阳性输血和最后一次抗体检测没有显示抗d之间的时间较短的受者将来可能会对d异体免疫。建立了一个回归模型来预测这些患者将来可能发生d -同种异体免疫的频率,以帮助解释伴随短暂血清学随访期的免疫血液学不确定性。方法:利用已发表的关于有意输注rhd阳性红细胞并连续进行抗体筛查的文献,以及未发表的数据集,构建回归模型,以证明在指数输注后6个月内进行了d -同种异体免疫的受者的d -同种异体免疫时间。然后将该模型应用于一系列rhd阴性的住院患者,这些患者接受了至少一个单位的rhd阳性红细胞,但没有进行d -同种异体免疫,但血清学随访时间少于6个月,以衡量他们对d -同种异体免疫率的贡献。结果:总体而言,d -异体免疫率为21/105(20.0%)。39例患者的最后一次有记录的抗体筛查是在输血指数rh阳性后14天至6个月之间进行的,这些患者被纳入加权模型。应用该模型后,d -异体免疫率上升至26.3%。结论:使用加权模型可以帮助减少免疫血液学的不确定性,这种不确定性伴随着红细胞异体免疫研究中血清学随访时间相对较短的患者的纳入。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transfusion
Transfusion 医学-血液学
CiteScore
4.70
自引率
20.70%
发文量
426
审稿时长
1 months
期刊介绍: TRANSFUSION is the foremost publication in the world for new information regarding transfusion medicine. Written by and for members of AABB and other health-care workers, TRANSFUSION reports on the latest technical advances, discusses opposing viewpoints regarding controversial issues, and presents key conference proceedings. In addition to blood banking and transfusion medicine topics, TRANSFUSION presents submissions concerning patient blood management, tissue transplantation and hematopoietic, cellular, and gene therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信